Agreed. I should have said including a large upfront payment, use these techniques to lower the cash burden. Example if they bought all the shares in the tradable float right now that would be less than 50%, but if you are paying 5x or 10x the current sp, buying some would reduce cash needed. Or adding buyout for one indication and CVR for another indication.

Right now the company is still cash poor, so still some concern getting full worth on all indications. It will be interesting to see what happens if they get more good cancer data the next month or two.